



PRESS RELEASE

MolMed and Megapharm enter into a term sheet to commercialise Zalmoxis® in Israel

Milan (Italy), December 1st, 2016 – MolMed S.p.A. (“MolMed”) and Megapharm Ltd (“Megapharm”) today announce they signed a term sheet defining the main terms and conditions for supply, registration, promotion and distribution of Zalmoxis in Israel. Within April 30th, 2017, the terms contained in today’s agreement shall be incorporated into a definitive contract, pursuant to which Megapharm will be appointed by MolMed as the exclusive licensee, under certain terms and conditions, to market, sell and distribute Zalmoxis in Israel.

Zalmoxis is conditionally authorised by the European Commission for adult patients affected by leukaemia or other high-risk haematological malignancies, and is the first patient-specific cell therapy used in combination with haplo-identical haematopoietic stem cell transplant (haplo-HSCT).

Under the terms and conditions of today’s agreement, after the signature of the definitive contract Zalmoxis will be distributed and marketed by Megapharm, once approved by the Israeli Ministry of Health (MOH) and included in the Israeli National Health Basket of drugs by the MOH. Furthermore, Megapharm will be responsible for conducting all regulatory activities after marketing authorisation in Israel, including market access and price & reimbursement.

Riccardo Palmisano, MolMed’s CEO, commented: *“We are glad to announce this agreement with Megapharm, one of the leading private biotech marketing companies in Israel: it represents an excellent starting point in the Zalmoxis commercialisation activity. MolMed is evaluating the best possible option to successfully commercialise Zalmoxis in the main European countries, and today’s agreement is a very important first step, as Israeli market, although not huge, is one of the most sophisticated and technologically advanced, both in terms of healthcare practices and clinical competencies.”*

“Megapharm is proud to partner with MolMed, a pioneer in the field of cell therapy”, said Miron Drucker, Megapharm’s CEO, “Megapharm has set a target to make available to patients in Israel, innovative state of the art treatments, such as Zalmoxis. Megapharm will work closely with MolMed on defining the right pathway to enter the Israeli market.”

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
info@molmed.com - www.molmed.com

Share capital € 19,841,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159



PRESS RELEASE

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6 is an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP manufacturing of viral vectors and patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

About Megapharm

Megapharm Ltd. Is a leading Israeli private pharma marketing company, exclusively represents number of major American, European and Japanese pharmaceutical companies. Megapharm provides its partners with the full commercial capabilities, including registration, market access & reimbursement, sales & marketing, etc. Megapharm has demonstrated dynamic sales growth by developing a strong company presence and expertise in select therapeutic areas and proven track record for obtaining reimbursement and inclusion of its products in all the Health Funds in Israel.

For further information:

MolMed:

Laura Villa

Investor Relations & Communication Director

phone: +39 02 21277.205

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Megapharm:

Ran Levin

Head of Business Development

phone: +972 9 760 4596

fax: +972 9 7604514

e-mail: info@megapharm.co.il

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@segrp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A..